About Careers Internship MedBlog Contact us

Costliest Medicine Received US Regulators Approval

by Ramya Rachamanti on May 27, 2019 at 7:17 PM
Costliest Medicine Received US Regulators Approval

US FDA has approved the most expensive medicine named Zolgensma sold by the Novartis at $2.125 million (around Rs. 14cr) to treat spinal muscular atrophy (SMA), a fatal spinal disease that kills nearly everyone within few years, for children aged below two after doing a genetic test.

The drug targets a defective gene that weakens a child's muscles that they become unable to move, and finally unable to swallow or breathe. It occurs in about 400 babies born in the US every year. The therapy is a one-time infusion that takes about an hour.


Zolgensma acts by supplying a fresh copy of the faulty gene, allowing the nerve cells to start producing the needed protein that allows the baby to develop normally.

Babies with the most severe form of the disease who got Zolgensma within six months of birth had limited muscle problems. They stopped losing muscle control, but the medicine can't reverse the damage already done.

Early diagnosis and early treatment is crucial, so Novartis has been working with states to get genetic testing for newborns required at birth. Most states were expected to have that requirement by next year.

Side effects of this new drug includes vomiting and potential liver damage. Patients must be monitored thoroughly for the first few months after treatment.

One more medicine for the disease approved is Spinraza to be given once every four months, sold by Biogen which charges $750,000 for the first year and then $350,000 per year after that.

Source: Medindia
Font : A-A+



Recommended Readings

Latest Drug News

WHO Approves R21/Matrix-M, the World's Second Malaria Vaccine
R21/Matrix-M, the world's second malaria vaccine is readily deployable, and cost-effective making it prepared for distribution in areas where it is most essential.
New Inverse Vaccine Sparks Hope in Diabetes, Arthritis, and Crohn's Disease
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Costliest Medicine Received US Regulators Approval Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests